A wave of fresh data is reshaping how doctors treat metastatic colorectal cancer (mCRC). First, researchers announced a major breakthrough with Temab‑A, an antibody‑drug conjugate that homes in on the c‑Met protein. Early trials suggest Temab‑A could become a lifeline for patients who have already tried two lines of therapy, offering a targeted option where few exist. At the 2025 CSCO meeting, Prof. Heinz‑Josef Lenz of USC Norris Cancer Center highlighted both the excitement and the hurdles surrounding immunotherapy for mCRC, stressing the need for better biomarkers and combination strategies. Meanwhile, a JAMA‑published ORCHESTRA trial dampened hopes that adding aggressive tumor‑removing surgery to standard palliative chemotherapy would extend survival for patients with multi‑organ metastases – the study found no significant benefit. In China, a Phase II study (NCT06202001) evaluated a triple regimen—irinotecan, TAS‑102, and bevacizumab—as second‑line treatment. The regimen proved safe and gave a clear survival edge, especially for patients whose primary tumor had already been removed. Together, these findings point to a more personalized future: targeting c‑Met with Temab‑A, refining immunotherapy approaches, and leveraging multi‑drug combos to improve outcomes for advanced colorectal cancer patients.
Read moreAt the European Society for Medical Oncology’s Breast Cancer Congress in Berlin (May 6‑8, 2026), Chinese researchers stole the spotlight with two game‑changing studies. The first, presented by Dr. Haoyu Wang, tested a new sequence of targeted drugs—pyrotinib followed by pertuzumab—for women with HER2‑positive breast cancer who were receiving neoadjuvant (pre‑surgery) therapy. The approach boosted the rate of complete tumor disappearance to 92.7% and cleared circulating tumor DNA (ctDNA) in 81.5% of patients after just two cycles. Those whose ctDNA vanished were far more likely to achieve a pathological complete response, and persistent ctDNA flagged a higher risk of recurrence. Safety was manageable, with no treatment‑related deaths and side‑effects similar to standard regimens. The second study tackled advanced triple‑negative breast cancer, a form that often resists chemotherapy. Researchers combined a bispecific immunotherapy antibody (Pumitamig) with a TROP‑2‑directed antibody‑drug conjugate (DB‑1305/BNT325), creating a chemo‑free first‑line regimen. Patients experienced strong tumor shrinkage and disease control regardless of PD‑L1 status, and side‑effects were mostly mild to moderate (low‑grade neutropenia, anemia, nausea, fatigue). No new safety signals emerged. Together, these trials illustrate China’s growing leadership in precision breast‑cancer care—offering more effective, less toxic options from early‑stage disease through advanced, hard‑to‑treat cases.
Read more